SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing market pressure after its CagriSema obesity drug did not achieve non-inferiority against Eli Lilly's competitor in a recent trial, fueling community debate over its competitive standing. However, strong early demand for its oral Wegovy, coupled with recent regulatory actions against compounded GLP-1 alternatives and ongoing share buybacks, is leading many to see the current sell-off as an overreaction and a potential buying opportunity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for BYSANTI, a new chemical entity with patent protection extending to 2044 for bipolar I disorder and schizophrenia. Community sentiment is largely bullish on significant upside potential and a possible short squeeze, though some express caution regarding a recent shelf offering and the drug's similarity to an existing therapy.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community debate intensifies around recent tariff rulings and new global levies, with widespread discussion focusing on their economic impact and concerns over the company's financial stability and potential dilution ahead of upcoming disclosures.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Enthusiasm for MoonLake Immunotherapeutics is surging following stellar Phase 2 S-OLARIS trial results for its lead drug sonelokimab in axial spondyloarthritis, with the community highlighting "best-in-class" efficacy, disease-modifying potential, strong financials, and anticipating further positive updates at its upcoming Investor Day.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following pivotal international approvals for its ANKTIVA cancer therapy in the EU and Saudi Arabia, complemented by robust revenue growth. The community is buzzing about the drug's global market expansion and potential as a chemotherapy-free cancer treatment, anticipating a substantial short squeeze.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's latest obesity drug trial underperformed Eli Lilly's, reigniting community discussion that Viking's competitive dual agonist VK2735 is now a highly attractive acquisition or partnership target for pharmaceutical giants eager to capture market share.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Recent positive clinical data for Arcellx's multiple myeloma CAR-T therapy, anito-cel, showcases strong efficacy and a differentiated safety profile, driving current conversation. An expanded strategic partnership and investment from Kite (Gilead), combined with the recent lifting of a partial clinical hold, reinforces market confidence and highlights the company's competitive edge in the cell therapy landscape.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its mainnet launch and institutional validation, including its Coinbase 50 index inclusion, drive bullish conviction in its utility and long-term potential, yet the community remains sharply divided amid persistent price drops leading to strong skepticism about the project's viability.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is actively discussed following its recent financial results, which showed solid U.S. same-store sales growth and a 15% dividend increase, alongside reports of prominent hedge funds, including Warren Buffett's Berkshire Hathaway, increasing their positions. The community is debating if its "Hungry for MORE" strategy and market leadership can continue to drive growth amidst a mixed restaurant sector and concerns over valuation.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending amid high anticipation for its BLA resubmission to the FDA for Deramiocel, with community discussion focused on the strong HOPE-3 data and speculation regarding recent FDA policy shifts and leadership dynamics affecting the approval process.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Granite Investment Partners LLC Sells 48,955 Shares of Belden Inc $BDC

Granite Investment Partners LLC cut its stake in shares of Belden Inc (NYSE:BDC - Free Report) by 31.3% during the third quarter, according to the company in its most recent Form 13F filing with the...

Channing Capital Management LLC Sells 214,689 Shares of Belden Inc $BDC

Channing Capital Management LLC lessened its position in Belden Inc (NYSE:BDC - Free Report) by 34.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional...

Is Belden (BDC) Stock Outpacing Its Computer and Technology Peers This Year?

Here is how Belden (BDC) and ATN International (ATNI) have performed compared to their sector so far this year.

Advisors Asset Management Inc. Purchases 9,090 Shares of Belden Inc $BDC

Advisors Asset Management Inc. boosted its position in Belden Inc (NYSE:BDC - Free Report) by 68.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC...

Belden (NYSE:BDC) Stock Price Expected to Rise, Benchmark Analyst Says

Benchmark boosted their price objective on shares of Belden from $145.00 to $175.00 and gave the stock a "buy" rating in a report on Friday...

Belden Q4 Earnings Call Highlights

Belden (NYSE:BDC) closed out 2025 with record fourth-quarter and full-year results, driven by continued growth in its solutions offerings and strong execution across its end markets. Management also...

Belden (NYSE:BDC) Posts Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Belden (NYSE:BDC - Get Free Report) issued its quarterly earnings data on Thursday. The industrial products company reported $2.08 earnings per share (EPS) for the quarter, beating analysts...

Belden Guides Q1 Revenues Above Estimates - Update

(RTTNews) - While reporting financial results for the fourth quarter on Thursday, networking solutions provider Belden, Inc. (BDC) provided its earnings, adjusted earnings and revenue guidance for...

Belden Reports Record Fourth Quarter and Full Year 2025 Results

Belden Inc. (NYSE: BDC) (Belden or the Company), a leading global supplier of specialty networking solutions, today reported fiscal fourth quarter and full year results for the period ended December...

Allianz Asset Management GmbH Has $3.13 Million Stake in Belden Inc $BDC

Allianz Asset Management GmbH cut its position in Belden Inc (NYSE:BDC - Free Report) by 46.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The...

Belden, Inc. engages in the provision of innovative signal transmission solutions. It operates through the Enterprise Solutions and Industrial Automation Solutions segments. The Enterprise Solutions segment offers network infrastructure solutions, as well as cabling and connectivity solutions for broadcast, commercial audio/video, and security applications. The Industrial Automation Solutions segment includes physical network and fieldbus infrastructure components and on-machine connectivity systems customized to end user, and original equipment manufacturer (OEM) needs. The company was founded by Joseph C. Belden in 1902 and is headquartered in St. Louis, MO.

BDC
Belden Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BDC News

BDCBelden Inc